Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644889 | 1.00 | CYP2C9 (0.47) | CYP2C9APPRAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL9870540 | 1.00 | CYP2C9 (0.47) | CYP2C9APPRAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL1911789 | 0.83 | CYP2C9 (0.65) | CYP2C9APPRAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL28620916 | 0.83 | CYP2C9 (0.65) | CYP2C9APPRAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL13123104 | 0.83 | CYP2C9 (0.65) | CYP2C9APPRAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL11192294 | 0.80 | CYP2C9 (0.43) | CYP2C9RAB9AL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL14279177 | 0.76 | MAPT (0.42) | CYP2C9APPL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL7188819 | 0.74 | ADORA2A (0.41) | CYP2C9APPRAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL18655709 | 0.72 | — | — | |
| SCHEMBL7618854 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314295-B1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX INC (CA) | 2015-01-28 | — | — | EP | disclosed |
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| US-5405826-A | Herbicidal pyridopyridazinones and pyridopyridazinethiones | RHONE POULENC AGRICULTURE LIMITED (GB) | 1995-04-11 | — | — | US | disclosed |
| US-5393730-A | Preemergence, postemergence herbicides | RHONE-POULENC AGRICULTURE LTD. (GB) | 1995-02-28 | — | — | US | disclosed |
| EP-0606843-A1 | Nicotinic acid derivative | RHONE POULENC AGRICULTURE LTD. (GB) | 1994-07-20 | — | — | EP | disclosed |
| EP-0555957-A1 | Pyrido 2,3-d pyridazine derivatives as herbicides | RHONE-POULENC AGRICULTURE LTD. (GB) | 1993-08-18 | — | — | EP | disclosed |
| US-4987232-A | ONE POT, GOOD YIELD | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ, B.V. (NL) | 1991-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | CYP2C9 3395/4885APP 430/4885RAB9A 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.